Literature DB >> 10790736

Elevated, sustained peroxynitrite levels as the cause of chronic fatigue syndrome.

M L Pall1.   

Abstract

The etiology of chronic fatigue syndrome (CFS) has been both obscure and highly contentious, leading to substantial barriers to both clear diagnosis and effective treatment. I propose here a novel hypothesis of CFS in which either viral or bacterial infection induces one or more cytokines, IL-1beta IL-6, TNF-alpha and IFN-gamma. These induce nitric oxide synthase (iNOS), leading to increased nitric oxide levels. Nitric oxide, in turn, reacts with superoxide radical to generate the potent oxidant peroxynitrite. Multiple amplification and positive feedback mechanisms are proposed by which once peroxynitrite levels are elevated, they tend to be sustained at a high level. This proposed mechanism may lower the HPA axis activity and be maintained by consequent lowered glucocorticoid levels. Similarities are discussed among CFS and autoimmune and other diseases previously shown to be associated with elevated peroxynitrite. Multiple pharmacological approaches to the treatment of CFS are suggested by this hypothesis.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10790736     DOI: 10.1054/mehy.1998.0825

Source DB:  PubMed          Journal:  Med Hypotheses        ISSN: 0306-9877            Impact factor:   1.538


  26 in total

1.  Elevated levels of protein carbonyls in sera of chronic fatigue syndrome patients.

Authors:  Iva V Smirnova; Martin L Pall
Journal:  Mol Cell Biochem       Date:  2003-06       Impact factor: 3.396

2.  Increased ventricular lactate in chronic fatigue syndrome. III. Relationships to cortical glutathione and clinical symptoms implicate oxidative stress in disorder pathophysiology.

Authors:  Dikoma C Shungu; Nora Weiduschat; James W Murrough; Xiangling Mao; Sarah Pillemer; Jonathan P Dyke; Marvin S Medow; Benjamin H Natelson; Julian M Stewart; Sanjay J Mathew
Journal:  NMR Biomed       Date:  2012-01-27       Impact factor: 4.044

3.  The Long Haul of COVID-19 Recovery: Immune Rejuvenation versus Immune Support.

Authors:  Jeffrey S Bland
Journal:  Integr Med (Encinitas)       Date:  2020-12

4.  Targeting mitochondrial dysfunction in the treatment of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) - a clinical audit.

Authors:  Sarah Myhill; Norman E Booth; John McLaren-Howard
Journal:  Int J Clin Exp Med       Date:  2012-11-20

5.  Lipid replacement/antioxidant therapy as an adjunct supplement to reduce the adverse effects of cancer therapy and restore mitochondrial function.

Authors:  Garth L Nicolson
Journal:  Pathol Oncol Res       Date:  2005-09-29       Impact factor: 3.201

Review 6.  Evidence of involvement of central neural mechanisms in generating fibromyalgia pain.

Authors:  Roland Staud
Journal:  Curr Rheumatol Rep       Date:  2002-08       Impact factor: 4.592

7.  Phospholipid supplementation can attenuate vaccine-induced depressive-like behavior in mice.

Authors:  Shaye Kivity; Maria-Teresa Arango; Nicolás Molano-González; Miri Blank; Yehuda Shoenfeld
Journal:  Immunol Res       Date:  2017-02       Impact factor: 2.829

Review 8.  Specific correlations between muscle oxidative stress and chronic fatigue syndrome: a working hypothesis.

Authors:  Stefania Fulle; Tiziana Pietrangelo; Rosa Mancinelli; Raoul Saggini; Giorgio Fanò
Journal:  J Muscle Res Cell Motil       Date:  2008-02-15       Impact factor: 2.698

9.  Mitochondrial Dysfunction and Chronic Disease: Treatment With Natural Supplements.

Authors:  Garth L Nicolson
Journal:  Integr Med (Encinitas)       Date:  2014-08

10.  Chronic fatigue syndrome and mitochondrial dysfunction.

Authors:  Sarah Myhill; Norman E Booth; John McLaren-Howard
Journal:  Int J Clin Exp Med       Date:  2009-01-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.